Skip to main content
. 2020 Feb 15;17(1):208–217. doi: 10.20892/j.issn.2095-3941.2019.0153

Figure 2.

Figure 2

Progression-free survival (PFS) with cetuximab in first-line recurrent and/or metastatic setting, compared between patients with wild-type and oncogene mutations for the following genes: (A) PIK3CA gene, (B) RAS gene, and (C) PIK3CA or RAS genes.